Lumos Pharma, Inc. (LUMO) Misses Q4 EPS by 304c

Lumos Pharma, Inc. (NASDAQ: LUMO) reported Q4 EPS of ($4.18), $3.04 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $2.05 million versus the consensus estimate of $0 .

For earnings history and earnings-related data on Lumos Pharma, Inc. (LUMO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79